STOCK TITAN

Rocket Pharmaceuticals (RCKT) CEO logs small stock sale to cover RSU tax obligations

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small share sale primarily tied to equity compensation. On common stock, he sold 2,409 shares in an open-market transaction at about $3.014 per share to pay tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

After this transaction, Shah directly holds 1,040,918 shares of common stock, and also reports indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that his holdings include RSUs that convert into common stock on a one-for-one basis.

Positive

  • None.

Negative

  • None.
Insider Shah Gaurav
Role CEO
Sold 2,409 shs ($7K)
Type Security Shares Price Value
Sale Common Stock 2,409 $3.014 $7K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,040,918 shares (Direct, null); Common Stock — 207,897 shares (Indirect, By Spouse)
Footnotes (1)
  1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
Shares sold 2,409 shares Open-market sale on 2026-05-19
Sale price per share $3.014 per share Common Stock sale on 2026-05-19
Direct holdings after sale 1,040,918 shares Common Stock directly owned following transaction
Trust indirect holdings 198,341 shares Held by Gaurav D. Shah Irrevocable Trust
Spouse indirect holdings 207,897 shares Common Stock held by spouse
Restricted Stock Units ("RSUs") financial
"Holdings include Restricted Stock Units ("RSUs") that convert to common stock"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
open-market sale financial
"transaction_action: "open-market sale" for the 2,409-share transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
tax withholding obligations financial
"sold by the Reporting Person in order to pay tax withholding obligations"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shah Gaurav

(Last)(First)(Middle)
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE

(Street)
CRANBURY NEW JERSEY 08512

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)05/19/2026S(2)2,409D$3.0141,040,918(1)D
Common Stock207,897IBy Spouse
Common Stock198,341IBy Gaurav D. Shah Irrevocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
2. The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.
/s/ Martin Wilson, as attorney-in-fact for Gaurav Shah05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RCKT CEO Gaurav Shah report?

Gaurav Shah reported selling 2,409 shares of Rocket Pharmaceuticals common stock. The shares were sold at about $3.014 each in an open-market transaction mainly to cover tax withholding obligations tied to vesting Restricted Stock Units (RSUs).

Why did the RCKT CEO sell 2,409 shares of common stock?

The 2,409 shares were sold to pay tax withholding obligations arising from the vesting of RSUs. This type of sale is typically a compensation-related, mechanical transaction rather than a discretionary portfolio move, according to the filing’s footnote.

How many RCKT shares does Gaurav Shah hold after the reported sale?

After the sale, Gaurav Shah directly holds 1,040,918 Rocket Pharmaceuticals shares. He also reports indirect ownership of 198,341 shares through an irrevocable trust and 207,897 shares held by his spouse, according to the Form 4 disclosure.

Are Restricted Stock Units (RSUs) included in the RCKT CEO’s reported holdings?

Yes. The filing notes that his holdings include Restricted Stock Units (RSUs). These RSUs convert into Rocket Pharmaceuticals common stock on a one-for-one basis, meaning each vested RSU becomes one share of common stock.